A multi-peptide DC-vaccine (ICT-107) was tested in a Phase I study, in newly diagnosed glioma patients with HLA-A1 or HLA-A2 and at least 1 TAA such as human epidermal growth factor receptor 2 (HER2), tyrosinase-related protein-2 (TRP-2), glycoprotein 100 (gp100), Melanoma Antigen-1 (MAGE-1), interleukin-13 receptor subunit alpha-2 (IL13-Ra2) or absent in melanoma 2 (AIM-2) in combination with standard chemotherapy and radiation. Here, IL13RA2 is linked to central nervous system cancer.